The stock of niche MRI developer Magna-Lab has been moved to NASDAQ's OTC Bulletin Board due tothe company's failure to meet minimum listing requirements onNASDAQ's Small-Cap exchange. Magna-Lab, of Hicksville, NY, hopesto return to the small-cap market
The stock of niche MRI developer Magna-Lab has been moved to NASDAQ's OTC Bulletin Board due tothe company's failure to meet minimum listing requirements onNASDAQ's Small-Cap exchange. Magna-Lab, of Hicksville, NY, hopesto return to the small-cap market after securing additional fundinglater this year, according to vice president John Haytaian.
Magna-Lab failed to meet NASDAQ's net worth requirement of$1 million for the small-cap market after a private equity placementfell through late last year and the company began using debt tofund operations (SCAN 12/14/94). NASDAQ made the decision to moveMagna-Lab's stock earlier this month. Ironically, Magna-Lab'sstock began moving upward after the move, Haytaian said.
Magna-Lab signed a letter of intent this month for a secondarypublic offering of $5 million to take place in the next two tothree months that will bring the company back into compliancewith NASDAQ requirements. The firm may also complete a privateequity placement by then, according to Haytaian.
The company has been rounding out its stable of distributionpartners for the Magna-SL 0.3-tesla scanner, which received Foodand Drug Administration clearance last year (SCAN 9/28/94). Magna-Labthis month signed an agreement with American Medical Concepts(AMCI) of Houston to distribute Magna-SL to the U.S. orthopedicmarket. The deal will complement an agreement with Beta-Numericsfor the fee-per-scan and mobile markets, as well as a deal withElscint for international sales that has not yet been finalized.
Magna-Lab this month completed the first installation of Magna-SLto MedCenter Imaging in San Antonio, TX. The installation tookonly two days, Haytaian said. Imaging services firm Health Imagesof Atlanta will be under contract by Magna-Lab to provide servicefor that unit, he said.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.